Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06455046

Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer

Efficacy and Safety of AK104 Combined With Pemetrexed, Carboplatin and Recombinant Human Adenovirus 5 Injection in Advanced Recurrent Cervical Cancer: a Multicenter, Single-arm, Prospective Phase II Clinical Study

Sponsor: Fujian Cancer Hospital

Conditions Cervical Cancer Recurrent

Interventions AK104 Recombinant Human Adenovirus 5 Injection

Updated 2 times since 2024 Last updated: Jun 6, 2024 Started: Oct 11, 2023 Primary completion: Oct 10, 2025 Completion: Oct 10, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cervical Cancer Recurrent and is currently actively recruiting participants. Fujian Cancer Hospital leads this study, which shows 2 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

2 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2

First recorded

Oct 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fujian Cancer Hospital
Zhangzhou Municipal Hospital of Fujian Province

Data source: Fujian Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Fuzhou, China